Article
Melanocortin receptor 4 as a new target in melanoma therapy: Anticancer activity of the inhibitor ML00253764 alone and in association with B-raf inhibitor vemurafenib.
Biochemical pharmacology - 1 Jan 2024
Orlandi Paola, Banchi Marta, Vaglini Francesca, Carli Marco, Aringhieri Stefano, Bandini Arianna, Pardini Carla, Viaggi Cristina, Lai Michele, Alì Greta, Ottani Alessandra, Vandini Eleonora, Guidi Patrizia, Bernardeschi Margherita, La Rocca Veronica, Francia Giulio, Fontanini Gabriella, Pistello Mauro, Frenzilli Giada, Giuliani Daniela, Scarselli Marco, Bocci Guido
Abstract excerpt
The aim of our study is to investigate in vitro and in vivo MC4R as a novel target in melanoma using the selective antagonist ML00253764 (ML) alone and in combination with vemurafenib, a B-rafV600E inhibitor. The human melanoma B-raf mutated A-2058 and WM 266-4 cell lines were used. An MC4R null A-2058 cell line was generated using a CRISPR/Cas9 system. MC4R protein expression was analysed by western blotting,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.